Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT06842160
Starting soon Observational

Photoplethysmography (PPG) Algorithm with Smartwatch in Evaluation of Atrial Fibrillation Burden After Catheter Ablation

NCT06842160 · tracked via the Priya Life Science China tracker
Sponsor
Beijing Anzhen Hospital
Phase
Observational
Started
2025-03-30
Last updated
2025-02-24

Condition(s) studied

Atrial Fibrillation (AF)

Investigational drug(s) / intervention(s)

intervention group

intervention group: A smart electrocardiogram watch based on the PPG algorithm for monitoring atrial fibrillation load after catheter ablation.

Study summary

The purpose of this study is to evaluate the effectiveness of a smart electrocardiogram watch based on the PPG algorithm in monitoring the atrial fibrillation burden of patients after catheter ablation.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Atrial fibrillation patients diagnosed by electrocardiogram 2. Received catheter ablation procedure 3. Willing to use long-range electrocardiogram monitoring equipment Exclusion Criteria: 1.Patients who are allergic to electronic devices or unable to wear watches

Primary outcome measure(s)

  • Incidence of Stroke — March 30, 2025 to March 30, 2035
    The rate of stroke occurrences in the study population, measured separately for each participant. The unit of measure will be the frequency of events (e.g., number of strokes per participant).
  • Incidence of Heart Failure — March 30, 2025 to March 30, 2035
    The rate of heart failure occurrences in the study population, measured separately for each participant. The unit of measure will be the frequency of events (e.g., number of heart failure episodes per participant).
  • All-Cause Mortality Rate — March 30, 2025 to March 30, 2035
    The rate of all-cause mortality in the study population, measured separately for each participant. The unit of measure will be the frequency of events (e.g., number of deaths per participant).
  • Cardiovascular Mortality Rate — March 30, 2025 to March 30, 2035
    The rate of cardiovascular-related mortality in the study population, measured separately for each participant. The unit of measure will be the frequency of events (e.g., number of cardiovascular-related deaths per participant).
  • Rate of Rehospitalization — March 30, 2025 to March 30, 2035
    The rate of rehospitalization due to any medical cause in the study population. The unit of measure will be the frequency of events (e.g., number of rehospitalization events per participant).
  • Incidence of Bleeding Events — March 30, 2025 to March 30, 2035
    The rate of bleeding events (such as major or minor bleeding) in the study population. The unit of measure will be the frequency of events (e.g., number of bleeding events per participant).
  • Postoperative Atrial Fibrillation Burden — March 30, 2025 to March 30, 2035
    The frequency and severity of atrial fibrillation episodes observed in participants after a surgical procedure, measured using data collected by an intelligent heart rate monitoring watch utilizing a PPG algorithm. The unit of measure will be frequency of events (e.g., number of episodes per participant).

Trial sites (1)

FacilityCityRegionStatus
Beijing Anzhen Hospital Beijing Beijing Municipality

More Beijing Anzhen Hospital trials in China

Safety and Efficacy of a Novel Composite-Tip Guiding Catheter in Transcarotid Artery Stenting Via Transradial Access Recruiting
A Multicenter Study of Artificial Intelligence Model for Fetal Congenital Heart Disease Starting soon
SAfety and eFfectiveness of cathetER Ablation for Atrial Fibrillation With Intracranial Hemorrhage (SAFER-AF) Recruiting
Digital Remote Management for Care and Continuous Optimization Versus Usual Care in Patients With Coronary Heart Disease (DigiCare-CHD) Starting soon
Standby Cannulated ECMO for High-Risk Percutaneous Coronary Intervention Recruiting

Other trials for the same condition

Pulsed Field Ablation Outcomes With Efficacy and Randomization in Atrial Fibrillation (POWER-AF) Recruiting
Nudging for Anticoagulation Adherence in Atrial Fibrillation Starting soon
PulseMagic™ TrueForce™ PAF NMPA Study Starting soon
Photoplethysmography (PPG) Algorithm With Smartwatch in Evaluation of Atrial Fibrillation Burden Starting soon
Testing the Performance of Smartphones and Their Accessories in Detecting Irregularly Irregular Heart Rhythm Enrolling by invitation
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06842160 on ClinicalTrials.gov ↗ ← All trials in China